Chairman, President & CEO

Thomas Okarma, MD, PhD

Dr. Okarma brings over 30 years’ experience as CEO of three publicly traded companies, including Geron Corporation, where he was responsible for the world’s first FDA authorized IND for human embryonic stem cells, a milestone in biotechnology. While at Geron, he also managed the development of Imetelstat, the world’s only telomerase inhibitor drug currently in advanced clinical testing for hematologic malignancies. Dr. Okarma was also a Senior Vice President of Rhone Poulenc Rorer, following their acquisition of his first company, Applied Immune Sciences. Under Dr. Okarma’s leadership, Regencor has attracted and retained highly trained and experienced employees, consultants, and CROs/CMOs.

Chief Scientific Officer 

Pilar Ruiz-Lozano, PhD

As a member of the Faculty at Stanford School of Medicine and the Sanford-Burnham-Prebys Institute, she pioneered the development of tissue engineering and epicardial biology to treat heart disease.  She led the discovery of the cardiac regenerative properties of recombinant human FSTL1 and the development of delivery modalities that are now licensed by Regencor, Inc.


Mark Mercola, PhD

Dr. Mercola is Professor of Medicine at Stanford and formerly was Professor of Bioengineering at the University of California, San Diego, the Sanford-Burnham-Prebys Institute and Harvard Medical School. He brings expertise in stem cell models of heart disease for drug development and was a co-discoverer of the regenerative properties of FSTL1.

Clinical Head EpicaBead Development

Nabil Dib, MD, FACC

Dr. Dib is the Director of Cardiovascular Research at Dignity Health in Phoenix, Arizona, and is the Founder and President of the International Society for Cardiovascular Translational Research. A Harvard-trained cardiologist, he is internationally recognized as an interventional cardiologist and pioneer in coronary infusion technologies. Dr. Dib has participated as an investigator in over 65 clinical trials of cardiovascular devices, and cell and gene therapies for cardiovascular disease. He is the inventor of the ND Infusion Catheter, a widely used FDA cleared medical device for the introduction of cells, biologicals and pharmaceuticals directly into coronary arteries.


Jane Lebkowski, PhD

President of R&D, Regenerative Patch Technologies. Dr. Lebkowski was previously CSO of Asterias, Inc., Senior VP and CSO of Geron Corporation, and VP of R&D at Rhone-Poulenc-Rorer. In these positions, she managed R&D of biologics, and cell and gene therapies for regenerative medicine applications. She advises on pre-clinical, regulatory and clinical product development.